54
Participants
Start Date
March 14, 2019
Primary Completion Date
April 27, 2022
Study Completion Date
April 27, 2022
PF-06939999 dose escalation
PF-06939999 orally at escalating doses on a continuous basis
PF-06939999 monotherapy
PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
PF-06939999 in combination with docetaxel
PF-06939999 orally on a continuous basis in combination with docetaxel
Inova Schar Cancer Institute, Fairfax
AdventHealth Orlando - Investigational Drug Services, Orlando
AdventHealth Orlando Infusion Center, Orlando
AdventHealth Orlando, Orlando
University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center, Miami
AdventHealth Celebration Infusion Center, Celebration
AdventHealth Medical Group Oncology Research at Celebration, Celebration
Henry-Joyce Cancer Clinic, Nashville
Oncology IDS Pharmacy, Nashville
St. Joseph Mercy Hospital, Ann Arbor
St. Joseph Mercy Brighton, Brighton
The University of Texas, Houston
NEXT Oncology, San Antonio
Scottsdale Healthcare Hospitals d/b/a HonorHealth, Scottsdale
Virginia G. Piper Cancer Pharmacy, Scottsdale
Keck Hospital of USC, Los Angeles
LAC + USC Medical Center, Los Angeles
USC Norris Comprehensive Cancer Center, Los Angeles
USC/Norris Comprehensive Cancer Center, Los Angeles
Keck Medical Center of USC Pasadena, Pasadena
Seattle Cancer Care Alliance, Seattle
University of Washington Medical Center, Seattle
Lead Sponsor
Pfizer
INDUSTRY